Prajnan Das1, Cathy Eng2, Miguel A Rodriguez-Bigas3, George J Chang3, John M Skibber3, Y Nancy You3, Dipen M Maru4, Mark F Munsell5, Marilyn V Clemons6, Scott E Kopetz2, Christopher R Garrett2, Imad Shureiqi2, Marc E Delclos6, Sunil Krishnan6, Christopher H Crane6. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: PrajDas@mdanderson.org. 2. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
PURPOSE: The goal of this phase 1 trial was to determine the maximum tolerated dose (MTD) of concurrent capecitabine, bevacizumab, and erlotinib with preoperative radiation therapy for rectal cancer. METHODS AND MATERIALS: Patients with clinical stage II to III rectal adenocarcinoma, within 12 cm from the anal verge, were treated in 4 escalating dose levels, using the continual reassessment method. Patients received preoperative radiation therapy with concurrent bevacizumab (5 mg/kg intravenously every 2 weeks), erlotinib, and capecitabine. Capecitabine dose was increased from 650 mg/m(2) to 825 mg/m(2) orally twice daily on the days of radiation therapy; erlotinib dose was increased from 50 mg orally daily in weeks 1 to 3, to 50 mg daily in weeks 1 to 6, to 100 mg daily in weeks 1 to 6. Patients underwent surgery at least 9 weeks after the last dose of bevacizumab. RESULTS: A total of 19 patients were enrolled, and 18 patients were considered evaluable. No patient had grade 4 acute toxicity, and 1 patient had grade 3 acute toxicity (hypertension). The MTD was not reached. All 18 evaluable patients underwent surgery, with low anterior resection in 7 (39%), proctectomy with coloanal anastomosis in 4 patients (22%), posterior pelvic exenteration in 1 (6%), and abdominoperineal resection in 6 (33%). Of the 18 patients, 8 (44%) had pathologic complete response, and 1 had complete response of the primary tumor with positive nodes. Three patients (17%) had grade 3 postoperative complications (ileus, small bowel obstruction, and infection). With a median follow-up of 34 months, 1 patient developed distant metastasis, and no patient had local recurrence or died. The 3-year disease-free survival was 94%. CONCLUSIONS: The combination of preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib was well tolerated. The pathologic complete response rate appears promising and may warrant further investigation.
PURPOSE: The goal of this phase 1 trial was to determine the maximum tolerated dose (MTD) of concurrent capecitabine, bevacizumab, and erlotinib with preoperative radiation therapy for rectal cancer. METHODS AND MATERIALS: Patients with clinical stage II to III rectal adenocarcinoma, within 12 cm from the anal verge, were treated in 4 escalating dose levels, using the continual reassessment method. Patients received preoperative radiation therapy with concurrent bevacizumab (5 mg/kg intravenously every 2 weeks), erlotinib, and capecitabine. Capecitabine dose was increased from 650 mg/m(2) to 825 mg/m(2) orally twice daily on the days of radiation therapy; erlotinib dose was increased from 50 mg orally daily in weeks 1 to 3, to 50 mg daily in weeks 1 to 6, to 100 mg daily in weeks 1 to 6. Patients underwent surgery at least 9 weeks after the last dose of bevacizumab. RESULTS: A total of 19 patients were enrolled, and 18 patients were considered evaluable. No patient had grade 4 acute toxicity, and 1 patient had grade 3 acute toxicity (hypertension). The MTD was not reached. All 18 evaluable patients underwent surgery, with low anterior resection in 7 (39%), proctectomy with coloanal anastomosis in 4 patients (22%), posterior pelvic exenteration in 1 (6%), and abdominoperineal resection in 6 (33%). Of the 18 patients, 8 (44%) had pathologic complete response, and 1 had complete response of the primary tumor with positive nodes. Three patients (17%) had grade 3 postoperative complications (ileus, small bowel obstruction, and infection). With a median follow-up of 34 months, 1 patient developed distant metastasis, and no patient had local recurrence or died. The 3-year disease-free survival was 94%. CONCLUSIONS: The combination of preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib was well tolerated. The pathologic complete response rate appears promising and may warrant further investigation.
Authors: Julio Garcia-Aguilar; David D Smith; Karin Avila; Emily K Bergsland; Peiguo Chu; Richard M Krieg Journal: Ann Surg Date: 2011-07 Impact factor: 12.969
Authors: J-P Machiels; C Sempoux; P Scalliet; J-C Coche; Y Humblet; E Van Cutsem; J Kerger; J-L Canon; M Peeters; S Aydin; S Laurent; A Kartheuser; B Coster; S Roels; J-F Daisne; B Honhon; L Duck; C Kirkove; M-A Bonny; K Haustermans Journal: Ann Oncol Date: 2007-01-05 Impact factor: 32.976
Authors: Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark Journal: J Clin Oncol Date: 2009-09-21 Impact factor: 44.544
Authors: C Bengala; S Bettelli; F Bertolini; S Salvi; S Chiara; C Sonaglio; L Losi; N Bigiani; G Sartori; C Dealis; N Malavasi; R D'Amico; G Luppi; B Gatteschi; A Maiorana; P F Conte Journal: Ann Oncol Date: 2008-12-18 Impact factor: 32.976
Authors: Glenda G Callender; Prajnan Das; Miguel A Rodriguez-Bigas; John M Skibber; Christopher H Crane; Sunil Krishnan; Marc E Delclos; Barry W Feig Journal: Ann Surg Oncol Date: 2009-10-22 Impact factor: 5.344
Authors: Douglas E Ney; Julie A Carlson; Denise M Damek; Laurie E Gaspar; Brian D Kavanagh; B K Kleinschmidt-DeMasters; Allen E Waziri; Kevin O Lillehei; Krishna Reddy; Changhu Chen Journal: J Neurooncol Date: 2014-12-19 Impact factor: 4.130
Authors: Thomas J George; Aaron J Franke; A Bapsi Chakravarthy; Prajnan Das; Arvind Dasari; Bassel F El-Rayes; Theodore S Hong; Timothy J Kinsella; Jerome C Landry; James J Lee; Arta M Monjazeb; Samuel A Jacobs; David Raben; Osama E Rahma; Terence M Williams; Christina Wu; C Norman Coleman; Bhadrasain Vikram; Mansoor M Ahmed Journal: Cancer Date: 2019-04-24 Impact factor: 6.860
Authors: Awalpreet S Chadha; Heath D Skinner; Jillian R Gunther; Mark F Munsell; Prajnan Das; Bruce D Minsky; Marc E Delclos; Deyali Chatterjee; Huamin Wang; Marilyn Clemons; Geena George; Pankaj K Singh; Matthew H Katz; Jason B Fleming; Milind M Javle; Robert A Wolff; Gauri R Varadhachary; Christopher H Crane; Sunil Krishnan Journal: PLoS One Date: 2016-06-23 Impact factor: 3.240
Authors: Kimberly M Arnold; Nicole J Flynn; Adam Raben; Lindsay Romak; Yan Yu; Adam P Dicker; Firas Mourtada; Jennifer Sims-Mourtada Journal: Cancer Growth Metastasis Date: 2018-03-09